Announcement: Temporary Total Depletion of US Licensed Yellow Fever Vaccine Addressed by Availability of Stamaril Vaccine at Selected Clinics
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-Vax) licensed in the United States, announced on February 22, 2018, that YF-Vax for civilian use is expected to be available from the manufacturer again by the end of 2018. However, YF-VAX might be available at some clinics, until remaining supplies at those sites are used up. Sanofi Pasteur applied and received approval from the US Food and Drug Administration (FDA) to make another yellow fever vaccine available in the United States under an investigational new drug (IND) program.* Manufactured by Sanofi Pasteur in France, this vaccine, Stamaril, is registered and distributed in more than 70 countries. It is comparable in safety and efficacy to YF-Vax.
In order to meet the requirements of the IND program, Sanofi Pasteur can provide Stamaril to only a limited number of clinics. Sanofi has identified sites throughout the United States to include in the program so patients can have continued access to yellow fever vaccine.
Travelers and health care providers can find locations that can administer Stamaril, and those clinics with remaining doses of YF-VAX, by visiting the yellow fever vaccination clinic search page. For information about which countries require yellow fever vaccination for entry and which countries the CDC recommends yellow fever vaccination, visit the CDC Travelers’ Health website (www.cdc.gov/travel).
*Although the name of the FDA program is "investigational new drug," Stamaril is not investigational or experimental. Stamaril has been used in European and other countries for decades but is not licensed in the United States. IND is the mechanism through which FDA gives approval for Stamaril to be imported.
- Page created: April 18, 2017
- Page last updated: February 22, 2018
- Page last reviewed: February 22, 2018
- Content source: